BioNxt advances sublingual everolimus ODF for transplant rejection study
BioNxt Solutions Inc. says it is advancing its proprietary sublingual everolimus oral dissolving film (ODF) for organ transplant rejection, and has initiated a large-animal pharmacokinetic study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.